Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 7/20 | 0.39 |
| ▸ | WNT3A | P56704 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20140053 | 1.00 | GRM1 (0.53) | GRM1CHRM1CHRM4SLC6A9PARP1 | |
| SCHEMBL20157096 | 1.00 | GRM1 (0.53) | GRM1CHRM1CHRM4SLC6A9PARP1 | |
| SCHEMBL20140581 | 0.84 | KDM4E (0.52) | — | |
| SCHEMBL20141104 | 0.84 | CHRM1 (0.46) | GRM1CHRM1CHRM4SLC6A9PARP1 | |
| SCHEMBL20140014 | 0.83 | GRM1 (0.54) | GRM1CHRM1CHRM4SLC6A9PARP1 | |
| SCHEMBL20140810 | 0.80 | CHRM1 (0.43) | GRM1CHRM1CHRM4PARP1PARP2 | |
| SCHEMBL20157522 | 0.80 | CHRM1 (0.43) | GRM1CHRM1CHRM4PARP1PARP2 | |
| SCHEMBL20140035 | 0.80 | GRM1 (0.52) | GRM1CHRM1CHRM4SLC6A9PARP1 | |
| SCHEMBL20142107 | 0.79 | GRM1 (0.47) | GRM1CHRM1CHRM4SLC6A9PARP1 | |
| SCHEMBL20140074 | 0.78 | MAPT (0.50) | CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018089433-A1 | PHENYL mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |